Monday November 21, 2022
Destiny Pharma’s AMR Paper
It is AMR Awareness Week! The World Health Organisation has declared that Anti-Microbial Resistance (AMR) is one of the top 10 global public health threats facing humanity. Destiny Pharma is […]
Friday November 18, 2022
Dr Bill Love speaks to Proactive Investors about how Destiny Pharma is addressing the Gl...
AMR is associated with the deaths of five million people worldwide each year. It has been estimated that, by 2050, the global death toll from AMR will rise to 10 […]
Tuesday November 15, 2022
XF-73 Dermal infection project advances into clinically enabling safety study with US Go...
Destiny Pharma plc (“Destiny Pharma” or “the Company”) XF-73 Dermal infection project advances into clinically enabling safety study as part of ongoing agreement with US Government’s NIAID Brighton, United Kingdom, […]
Monday November 14, 2022